Adalimumab
adalimumab-adaz
- Strength
- 20 mg/.2mL
- Form
- Injection, Solution
- Class
- Tumor Necrosis Factor Blocker
Sandoz Inc
Not stocked by us — reference only
adalimumab-adaz
Listed by Sandoz Inc
| Dosage form | Injection, Solution |
|---|---|
| Route | Subcutaneous |
| Drug class | Tumor Necrosis Factor Blocker |
| Approval route | BLA — biologic licence |
| NDC code | 61314-509 |
| FDA application | BLA761071 |
| Marketed since | July 2023 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
adalimumab-adaz
Sandoz Inc
Not stocked by us — reference only
adalimumab-adaz
Sandoz Inc
Not stocked by us — reference only
adalimumab-adaz
Sandoz Inc
Not stocked by us — reference only
adalimumab-adaz
Sandoz Inc
Not stocked by us — reference only
Cordavis Limited
Not stocked by us — reference only
Cordavis Limited
Not stocked by us — reference only
adalimumab-atto
Amgen USA Inc.
Not stocked by us — reference only
adalimumab-atto
Amgen USA Inc.
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.